Status:
COMPLETED
Hydrochlorothiazide and Risk of Skin Cancer
Lead Sponsor:
Canadian Network for Observational Drug Effect Studies, CNODES
Collaborating Sponsors:
Drug Safety and Effectiveness Network, Canada
Canadian Institutes of Health Research (CIHR)
Conditions:
Non-melanoma Skin Cancer
Melanoma
Eligibility:
All Genders
40+ years
Brief Summary
The purpose of this study is to determine whether the use of hydrochlorothiazide is associated with an increased risk of skin cancer compared with the use of angiotensin-converting enzyme (ACE) inhibi...
Detailed Description
The study objective is to determine whether the use of hydrochlorothiazide is associated with an increased risk of skin cancer compared with the use of angiotensin-converting enzyme (ACE) inhibitors. ...
Eligibility Criteria
Inclusion
- Patients aged 40 years or older (or 66 years or older in Alberta, Nova Scotia and Ontario) newly-treated with hydrochlorothiazide or an ACE inhibitor between April 1, 1995 and March 31, 2018 (or the latest date of data availability at each site)
Exclusion
- Patients with less than one year of health coverage before cohort entry
- Patients with a previous prescription of any antihypertensive drug at any time before cohort entry
- Patients with a diagnosis of any type of skin cancer (non-melanoma and melanoma) at any time before cohort entry
- Patients with a diagnosis of HIV at any time before cohort entry
- Patients with a history of solid organ transplant at any time before cohort entry
- Patients with less than one year of follow-up after cohort entry
Key Trial Info
Start Date :
May 27 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 5 2021
Estimated Enrollment :
2953748 Patients enrolled
Trial Details
Trial ID
NCT04334824
Start Date
May 27 2019
End Date
March 5 2021
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital
Montreal, Quebec, Canada, H3T1E2